{"id":2119,"date":"2026-07-06T12:00:24","date_gmt":"2026-07-06T12:00:24","guid":{"rendered":"https:\/\/askneurology.com\/index.php\/2026\/07\/06\/study-reports-alzheimers-treatment-gains-in-long-term-care\/"},"modified":"2026-07-06T12:00:24","modified_gmt":"2026-07-06T12:00:24","slug":"study-reports-alzheimers-treatment-gains-in-long-term-care","status":"publish","type":"post","link":"https:\/\/askneurology.com\/index.php\/2026\/07\/06\/study-reports-alzheimers-treatment-gains-in-long-term-care\/","title":{"rendered":"Study reports Alzheimer\u2019s treatment gains in long-term care"},"content":{"rendered":"

\"An<\/a><\/p>\n

Top-line data from a real-world study suggest that Zunveyl<\/a> (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer\u2019s disease<\/a>.<\/p>\n

The BEACON study evaluated provider-reported outcomes from 21 investigators treating 162 long-term care patients who received routine clinical care with Zunveyl for three months to a year.<\/p>\n

\u201cWe believe that long-term care patients with Alzheimer\u2019s disease remain underrepresented in traditional clinical datasets despite representing a significant and clinically complex treatment population,\u201d Michael McFadden, CEO of Alpha Cognition, the company that developed Zunveyl, said in a company press release<\/a>. \u201cBEACON provides valuable real-world insights into the treatment experience of long-term care patients with Alzheimer\u2019s disease receiving ZUNVEYL.\u201d<\/p>\n

\n Recommended Reading<\/span>\n
\n
\n \"A\n <\/div>\n
\n
\n May 4, 2026<\/span>
\n\t\t News<\/a><\/span>
\n\t\t by Marisa Wexler, MS<\/a><\/span>\n <\/div>\n

<\/a><\/p>\n

FDA approves Auvelity to treat Alzheimer\u2019s-related agitation<\/h3>\n

\n <\/p><\/div>\n<\/div>\n<\/div>\n

Zunveyl studied in long-term care<\/h3>\n

Erik Cabrera, MD, board-certified psychiatrist and long-term care practitioner, added that \u201cthe importance of the BEACON study lies in its focus on the patients we care for every day in long-term care facilities\u2014individuals with Alzheimer\u2019s disease whose cognitive decline is often accompanied by neuropsychiatric symptoms, functional impairment, and substantial medication burden.\u201d<\/p>\n

Zunveyl, previously known as\u00a0ALPHA-1062, is an oral delayed-release formulation of benzgalantamine, a prodrug of galantamine, approved<\/a> to treat adults with mild-to-moderate Alzheimer\u2019s disease. Once inside the body, it is converted into galantamine. Galantamine,<\/a> also approved to treat Alzheimer\u2019s, works by helping increase the availability of acetylcholine, a brain signaling molecule involved in learning, thinking, and memory.<\/p>\n

FDA\u2019s approval of Zunveyl was based on bioequivalence studies<\/a> in healthy volunteers, which demonstrated that it delivers levels of galantamine to the body equivalent to those of its reference treatment. Zunveyl is designed to remain inactive as it passes through the stomach and is later converted into galantamine, which may improve its tolerability profile and reduce gastrointestinal symptoms associated with galantamine treatment.<\/p>\n

The BEACON study was a Phase 4 retrospective observational study designed to capture real-world evidence, reflecting how the therapy performs in everyday clinical practice. It evaluated provider-reported outcomes in long-term care patients with mild-to-moderate Alzheimer\u2019s treated with Zunveyl after prior treatment with acetylcholinesterase inhibitors, the class of Alzheimer\u2019s therapies<\/a> to which Zunveyl belongs.<\/p>\n

As a retrospective observational study, BEACON was not designed to establish causality. Still, across treated individuals, providers reported improvements in multiple areas affected by Alzheimer\u2019s disease.<\/p>\n

Providers report gains with treatment<\/h3>\n

Nearly all providers (98%) reported an overall favorable treatment experience with Zunveyl. Providers reported cognitive improvements in 92% of patients, while 71% had favorable observations related to activities of daily living after starting treatment.<\/p>\n

Providers also reported improvements in neuropsychiatric symptoms in 93% of those treated with Zunveyl. They also reported delayed initiation or discontinuation of concomitant psychotropic medications, including antipsychotics and anxiolytics, in 80% of patients. Providers also reported improvement in sleep-related issues in 72% of affected patients.<\/p>\n

Among those who had experienced gastrointestinal side effects with previous acetylcholinesterase inhibitors, providers reported favorable gastrointestinal tolerability observations in 89% after treatment with Zunveyl.<\/p>\n

\u201cThe provider-reported observations from BEACON provide descriptive real-world information regarding treatment experiences among long-term care patients receiving ZUNVEYL,\u201d Cabrera said. \u201cWhile the study was not designed to establish causality, these findings may help inform clinical discussions and future research in this challenging patient population.\u201d<\/p>\n

Alpha Cognition has now initiated RESOLVE, a Phase 4 (NCT07633470)<\/a> study evaluating Zunveyl in people with mild-to-moderate Alzheimer\u2019s disease, with the first participant recently enrolled. The trial will further evaluate Zunveyl\u2019s tolerability profile and treatment experience in routine clinical practice, while also exploring changes in Alzheimer\u2019s-related neuropsychiatric symptoms. Alpha Cognition said data from the study\u00a0could support<\/a> future regulatory discussions and help inform physicians and payers about Zunveyl\u2019s tolerability profile.<\/p>\n

<\/p>\n

The post Study reports Alzheimer\u2019s treatment gains in long-term care<\/a> appeared first on Alzheimer’s News Today<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily […]<\/p>\n","protected":false},"author":2,"featured_media":2120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[25],"tags":[],"class_list":["post-2119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzheimer"],"_links":{"self":[{"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/posts\/2119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/comments?post=2119"}],"version-history":[{"count":0,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/posts\/2119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/media\/2120"}],"wp:attachment":[{"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/media?parent=2119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/categories?post=2119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/askneurology.com\/index.php\/wp-json\/wp\/v2\/tags?post=2119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}